American Academy of Neurology (AAN) 2022 Annual Meeting
Seattle, US 02 April 2022 - 07 April 2022
MS patients on certain DMTs may have limited protection from COVID-19 vax
The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.
MS patients on certain DMTs may have limited protection from COVID-19 vax
30 May 2022
Keto diet: Is there good evidence in MS?
A diet rich in fat but low in carbohydrates, popularly known as the ketogenic or “keto” diet, offers clinical benefits to patients with relapsing multiple sclerosis (MS) in a phase II study. Quality of life (QoL) likewise improved, and so did disability.
Keto diet: Is there good evidence in MS?
23 May 2022
Sustained benefits with ocrelizumab in relapsing-remitting MS
Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.
Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022
No apparent link between COVID-19 vax and cerebrovascular outcomes
Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.
No apparent link between COVID-19 vax and cerebrovascular outcomes
13 May 2022
How does IV edaravone fare for ALS in the real world?
Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.
